Objectives: Enterobacteriaceae clinical isolates showing amikacin resistance (MIC 64 to .256 mg/L) in the absence of 16S rRNA methyltransferase (MTase) genes were found. The aim of this study was to clarify the molecular mechanisms underlying amikacin resistance in Enterobacteriaceae clinical isolates that do not produce 16S rRNA MTases.
Introduction
Aminoglycosides have been widely used for the treatment of bacterial infections caused by Gram-negative and Gram-positive bacteria in combination with b-lactams. 1 However, bacteria are known to acquire various mechanisms of resistance to aminoglycosides. 2 In Enterobacteriaceae, the acquisition of plasmidmediated 16S rRNA methyltransferase (MTase) genes such as armA, rmtB and rmtC has been reported worldwide and is becoming a major clinical concern because these MTases confer a high level of resistance to clinically important aminoglycosides including amikacin. 3 We previously reported that 16S rRNA MTase-producing Enterobacteriaceae showing a very high level of amikacin resistance (MIC ≥256 mg/L) have already spread in Japanese clinical settings, although the prevalence is very low. 3, 4 This survey led us to realize that the high amikacin resistance (MIC ≥256 mg/L) in Enterobacteriaceae mostly depends on 16S rRNA MTase production and at the same time raises the question of what resistance determinant is involved in amikacin resistance in Enterobacteriaceae strains without 16S rRNA MTase genes.
Aminoglycoside 6 ′ -N-acetyltransferases, AAC(6 ′ ), which acetylate the amino group at the 6 ′ -position of aminoglycosides, and aminoglycoside 3 ′ -O-phosphotransferases, APH(3 ′ ), which phosphorylate the hydroxyl group at the 3 ′ -position of aminoglycosides, are known to underlie amikacin resistance by disrupting the ability of aminoglycosides to bind to target 16S rRNA molecules. 5, 6 Several new AAC(6 ′ ) enzymes, such as AAC(6 ′ )-Iad, 7 AAC(6 ′ )-Iae, 8 AAC(6 ′ )-Iaf, 9 AAC(6 ′ )-Iaj 10 and AAC(6 ′ )-Iag, 11 have been reported exclusively in amikacin-resistant non-fermenting Gram-negative pathogens over the last 10 years in Japan, but it remains unclear whether these AAC (6 ′ ) enzymes are involved in amikacin resistance in Enterobacteriaceae. The aim of this study was thus to clarify the molecular mechanism underlying amikacin resistance in Enterobacteriaceae isolates that do not produce 16S rRNA MTases. Our study shows that Enterobacteriaceae clinical isolates have continuously acquired either amikacin acetyltransferases or 16S rRNA MTases to enable amikacin resistance.
Materials and methods

Bacterial strains
Fourteen amikacin-resistant (MIC ≥64 mg/L) Enterobacteriaceae clinical isolates (3 Escherichia coli, 4 Klebsiella pneumoniae, 2 Proteus mirabilis and 5 Serratia marcescens) were used in this study.
Susceptibility testing
MICs were determined with the agar dilution method.
12 E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 strains were used as quality controls.
Detection of amikacin resistance genes by PCR
Detection of aminoglycoside resistance 16S rRNA MTase genes was performed as described previously. 13 The presence of aac(6 ′ )-Ia and aac(6 ′ )-Ib, which are prevalent among Enterobacteriaceae as determining factors of amikacin resistance, was determined by PCR using the primers listed in Table S1 (available as Supplementary data at JAC Online).
Conjugation and transformation
E. coli CSH2 (rifampicin r ) was used as the recipient for conjugation. The conjugants were selected on LB agar plates containing 2 mg/L amikacin and 100 mg/L rifampicin.
14 Plasmids of the S. marcescens NUBL-11663 strain were extracted and electroporated into E. coli DH10B. The transformants were selected on LB agar plates supplemented with 2 mg/L amikacin.
Cloning of aac(6 ′ )-Ian
The p11663 plasmid was extracted from the E. coli DH10B transformant using the QIAGEN Plasmid Midi Kit (Qiagen) and partially digested with Sau3AI. The digested fragments were ligated to the pBC-SK+ vector previously digested with BamHI, dephosphorylated and then introduced into E. coli DH5a. The transformants were selected on LB agar plates supplemented with 30 mg/L chloramphenicol and 2 mg/L amikacin.
Complete nucleotide sequence of p11663
Plasmids were extracted from an E. coli DH10B transformant carrying p11663 as described above and subjected to electrophoresis with a CHEF-DR III system (Bio-Rad). The extracted plasmids were digested with S1 nuclease (Takara) and subjected to electrophoresis. The DNA band corresponding to p11663 was extracted using a Wizard SV Gel and PCR Clean-Up System (Promega). The sequence of p11663 was generated using paired-end libraries with 100 bp inserts on an Illumina Hiseq 2000 system. A velvet de novo assembler (velvet_1.2.03) was used to generate contigs from the reads. The gaps were closed by PCR and cloning experiments and followed by sequencing. The nucleotide sequences were analysed by GeneMark. hmm for Prokaryotes (http://exon.gatech.edu/GeneMark/gmhmmp.cgi) and BLAST programs (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
PCR cloning of bla The region including bla TLA-3 and its putative promoter was amplified with the primers listed in Table S1 , cloned into pBC-SK+ and introduced into E. coli DH5a. The transformants were selected on LB agar plates supplemented with 2 mg/L ceftazidime and 30 mg/L chloramphenicol.
Expression and purification of recombinant AAC(6 ′ )-Ian
The aac(6 ′ )-Ian gene was amplified with the primers listed in Table S1 and cloned into a pET22b(+) vector. The resultant plasmid (pET-AAC) was introduced into E. coli BL21(DE3)pLysS. The cells were cultured in LB broth containing 100 mg/L ampicillin and 30 mg/L chloramphenicol at 378C. When the OD at 610 nm reached 0.4, IPTG was added and the culture was further continued. The cells were collected, resuspended in PBS (pH 7.4) and disrupted with a French press. After ultracentrifugation, the supernatant was bound with 2 mL of Ni Sepharose TM 6 Fast Flow (GE Healthcare) and eluted with PBS containing 500 mM imidazole. The eluted protein was buffer-exchanged to PBS containing 20 mM imidazole and loaded onto a HisTrap TM HP column (GE Healthcare). The protein was eluted with a linear gradient of 20-500 mM imidazole. The collected protein was dialysed against 20 mM Bis-Tris buffer (pH 6.0) containing 50 mM NaCl, loaded onto a Mono Q column (GE Healthcare) and eluted with a linear gradient of 50 -500 mM NaCl. The eluted protein was concentrated, loaded onto a HiLoad 16/60 Superdex 200 pg column (GE Healthcare) and eluted with 20 mM Tris-HCl (pH 7.5) buffer containing 100 mM NaCl. The eluted protein was stored at 2808C until use.
Thin-layer chromatography (TLC) analysis of aminoglycoside acetylation by recombinant AAC(6 ′ )-Ian
Acetylation of aminoglycosides using recombinant AAC(6 ′ )-Ian was performed as described previously. 9 Briefly, each aminoglycoside solution (2 mM) was mixed with 2 mM acetyl coenzyme A (acetyl-CoA) and recombinant AAC(6 ′ )-Ian (2.5 mg) in 50 mL of PBS (pH 7.4) and then incubated at 378C for 16 h. Each mixture was applied to a TLC Silica Gel 60 F254 (Merck) and then developed with 5% phosphate potassium solution. Ninhydrin (Wako) was overlaid on silica gels to detect aminoglycoside derivatives.
HPLC
HPLC was also performed to identify the acetylation of aminoglycosides. AAC(6 ′ )-Iad, the positive control for the AAC(6 ′ ) group enzyme, was purified as described previously. 7 The purified AAC(6 ′ )-Iad or AAC(6 ′ )-Ian (5 mg) was added to 250 mL reaction mixtures containing 50 mM Tris-HCl buffer (pH 7.6), 15 mM MgCl 2 , 4 mM acetyl-CoA and 6 mM arbekacin or 10 mM neomycin. The incubation was performed at 378C for 30 min and equal volumes of 2-propanol and the derivatization reagent were added. 15 After incubation for 10 min at 608C, the sample was loaded onto a Chemcobond 5-ODS-H column (4.6×100 mm; Chemco Scientific) equipped with an Agilent 1100 HPLC system (Agilent Technologies). The mobile phase was the same as that described previously. 7 
Nucleotide sequence accession number
The complete nucleotide sequence of p11663 presented in this study has been deposited in GenBank under accession no. AP014611.
Results and discussion
Detection of AAC(6 ′ ) group enzyme gene in amikacin-resistant Enterobacteriaceae Fourteen amikacin-resistant Enterobacteriaceae without 16S rRNA MTase genes are listed in Table 1 . For these isolates, the presence of aac(6 ′ )-Ia and aac(6 ′ )-Ib was first explored by PCR and the results are summarized in Table 1 . Nine strains were found to carry aac(6 ′ )-Ia or aac(6 ′ )-Ib, but five strains (one E. coli, three S. marcescens and one P. mirabilis) gave negative results when evaluating resistance genes by PCR and these strains were predicted to have unknown mechanisms underlying amikacin resistance such as a new AAC(6 ′ ) group enzyme. S. marcescens strain NUBL-11663 showed a high level of resistance to amikacin (MIC 128 mg/L). We therefore decided to focus on clarifying the molecular mechanism underlying the amikacin resistance of the S. marcescens NUBL-11663 strain.
Transfer of amikacin resistance and cloning resistance determinants
The amikacin-resistant phenotype of the S. marcescens NUBL-11663 strain was successfully co-transferred with b-lactam resistance to E. coli strain CSH2 by conjugation. Introduction of plasmids extracted from the NUBL-11663 strain by electroporation also conferred amikacin resistance to E. coli DH10B (Table 2 ). These results indicate that the amikacin resistance determinant was located on the plasmids. We extracted plasmids from the E. coli DH10B transformant and identified one plasmid, named p11663, with a size of 170 kb ( Figure S1 ). Next, we attempted to isolate the amikacin resistance determinant located on p11663 by a cloning experiment and obtained one plasmid (pBC-amk) carrying a 1.2 kb insert by selection using amikacin. This 1.2 kb insert had one 573 bp ORF, encoding a protein consisting of 190 amino acids. A homology database search revealed that this protein has a coenzyme A-binding pocket, assigned to be a putative GCN5-like N-acetyltransferase, and has 97% amino acid identity to aminoglycoside 6 ′ -N-acetyltransferase, AAC(6 ′ ), of a whole genomedetermined Acinetobacter baumannii AYE strain (GenBank accession no. CU459141), 16 although the function of AAC(6 ′ ) of A. baumannii AYE has not been elucidated yet. Thus, the gene we isolated was predicted to encode an AAC(6 ′ ) conferring amikacin resistance and termed as AAC(6 ′ )-Ian. AAC(6 ′ )-Ian has low amino acid identity (,25%) to the functionally determined AAC(6 ′ ) group enzymes shown in Figure 1 .
Antimicrobial susceptibility testing
The MICs of various aminoglycosides for the parent S. marcescens NUBL-11663 and E. coli DH10B transformant strains are shown in E. coli DH10B naturally shows resistance to streptomycin.
Novel antibiotic resistance genes aac(6 ′ )-Ian and bla TLA-3 Table 2 . A parent S. marcescens NUBL-11663 strain showed resistance to a variety of aminoglycosides, 4,6-disubstituted 2-deoxystreptamines (DOS), 4,5-disubstituted 2-DOS, streptomycin and spectinomycin. The E. coli DH10B transformant showed an aminoglycoside resistance profile very similar to that of the parent strain. In E. coli DH5a carrying aac(6 ′ )-Ian, increased MICs were observed for 4,6-disubstituted 2-DOS except for gentamicin and 4,5-disubstituted 2-DOS, but not for the other aminoglycosides. This aminoglycoside resistance phenotype conferred by the production of AAC(6 ′ )-Ian was quite similar to that conferred by other aminoglycoside AAC(6 ′ ) group enzymes. 7 -11 The E. coli DH10B transformant harbouring p11663 demonstrated gentamicin and spectinomycin resistance that was not observed in E. coli DH5a carrying aac(6 ′ )-Ian, indicating that p11663 carried additional aminoglycoside resistance determinants other than aac(6 ′ )-Ian (discussed below). Regardless, these findings clearly show that the production of AAC(6 ′ )-Ian was mainly responsible for the amikacin resistance in the S. marcescens NUBL-11663 strain.
Complete nucleotide sequence of p11663 and genetic environment of aac(6 ′ )-Ian
The circular map of p11663 is shown in Figure 2 (a). Plasmid p11663 had a length of 169829 bp and belonged to incompatibility group A/C2 with a broad host range. The average G+ C content of p11663 was 52.0%. Plasmid comparative analysis revealed that the backbone of p11663 exhibited the highest similarity to that of plasmid pP91278 from a Photobacterium damselae subsp. piscicida isolate from the USA (GenBank accession no. AB277724). 17 The genetic environments of the newly identified aac(6 ′ )-Ian are shown in Figure 2(b) . The backbone elements upstream of aac(6 ′ )-Ian correspond partially to those found in the pHH1107 plasmid (GenBank accession no. FJ012881), which is a low-GC plasmid recovered from soil. 18 Heuer et al. 18 suggested that the original host of these low-GC antibiotic plasmids may be Acinetobacter species. The IS1106-like element, which was located at the 5 ′ -end of aac(6 ′ )-Ian, appeared to be inserted into a genetic region similar to the backbone sequence of the pHH1107 plasmid because a duplicated 8 bp sequence (CTGGCGAA) was found on both sides of the IS1106-like element, which is a hallmark of a previous insertion event. The aac(6 ′ )-Ian gene and IS1106-like element were flanked by two copies of a unique region (sequence 1) including an ISCR-like element. The genetic region including the aac(6 ′ )-Ian gene and its upstream 16 bp and downstream 151 bp had 94% nucleotide identity to those located in the chromosomal DNA of the A. baumannii AYE strain (GenBank accession no. CT025832) (Figure 2b ). The aac(6 ′ ) gene of A. baumannii AYE was flanked by two copies of ISCR-like elements that were quite different from those surrounding aac(6 ′ )-Ian. A similar AAC(6 ′ ) enzyme was found in A. baumannii (NCBI Reference Sequence WP_000960976), although its enzymatic function has not been evaluated; thus, aac(6 ′ )-Ian mediated by p11663 of the S. marcescens NUBL-11663 strain and aac(6 ′ ) found in A. baumannii strains may have evolved from a common ancestor.
Other antibiotic resistance genes in p11663
Another notable antibiotic resistance gene found in p11663 was bla TLA-3 , a new variant of the TLA-type ESBL gene. TLA-type b-lactamase was identified for the first time in Asian countries including Japan. TLA-3 has 93% and 52% amino acid identity to TLA-1, found in plasmids of Enterobacteriaceae clinical isolates exclusively from Latin America (Figure S2) , 19 -21 and TLA-2, found in the plasmid pRSB101 recovered from a wastewater treatment plant, 22 respectively. The introduction of a recombinant plasmid carrying bla TLA-3 (pBC-TLA-3) conferred resistance to ceftazidime, cefotaxime and cefepime, but not to cefmetazole and meropenem ( Table 2 ). The resistance to ceftazidime was reduced in the presence of clavulanic acid. These resistant phenotypes, the preferred b-lactam substrate and the high sensitivity to the b-lactamase inhibitor of TLA-3 correspond well to the characteristics of typical ESBLs belonging to class A b-lactamases. 23 The surrounding genetic organization of bla TLA-3 is largely different from that of bla TLA-1 of pRZA92 (GenBank accession Novel antibiotic resistance genes aac(6 ′ )-Ian and bla no. AF148067) from the E. coli strain R170 (Figure 2b ). 20 Only the 1.2 kb sequence containing bla TLA-3 and its upstream and downstream region showed 91% nucleotide identity to the sequences covering bla TLA-1 and its surrounding region.
In addition, bla TEM (which encodes a TEM-type b-lactamase with F100L substitution relative to TEM-208), bla SCO-1 (carbenicillinase gene) and aac(3)-II were present in the p11663 plasmid (Figure 2a) . The aac(3)-II gene is a gentamicin resistance determinant in the S. marcescens NUBL-11663 strain.
Overexpression and purification of histidine-tagged AAC(6 ′ )-Ian E. coli BL21(DE3)pLysS and the pET22b(+) expression vector were used for overexpression and purification of C-terminus histidinetagged AAC(6 ′ )-Ian. E. coli BL21(DE3)pLysS carrying pET22b(+) was susceptible to amikacin (MIC ≤0.25 mg/L), whereas E. coli BL21(DE3)pLysS carrying pET-AAC showed resistance to amikacin (MIC 32 mg/L), indicating that the production of histidine-tagged AAC(6 ′ )-Ian was functional and responsible for amikacin resistance in E. coli BL21(DE3)pLysS (data not shown).
Acetylation of aminoglycosides by AAC(6 ′ )-Ian
TLC analysis using a variety of aminoglycosides as a substrate was performed to determine the biochemical characteristics of AAC(6 ′ )-Ian. AAC(6 ′ )-Ian was predicted to be an acetyltransferase because it contained the acetyl-CoA-binding motif; thus, acetyl-CoA was first used as a cofactor in an in vitro reaction. The results of the TLC analysis are shown in Figure 3 . AAC(6 ′ )-Ian acetylated 4,6-and 4,5-disubstituted 2-DOS aminoglycosides, arbekacin, amikacin, tobramycin, kanamycin, gentamicin, isepamicin, sisomicin, netilmicin, neomycin and ribostamycin, which possess an amino group at the 6 ′ -position, although the modifications of gentamicin were only partial because it was a mixture of derivatives such as gentamicin C1a, C1 and C2 and gentamicin C1 has no amino group at the 6 ′ -position that can be modified. Apramycin and paromomycin with a hydroxyl group at the 6 ′ -position were not modified by AAC(6 ′ )-Ian. All aminoglycosides except gentamicin, whose MICs were increased by the production of AAC(6 ′ )-Ian in E. coli, were acetylated by the recombinant AAC(6 ′ )-Ian. The results of the HPLC analysis are shown in Table 3 . The retention times, which corresponded to the peak of o-phthalaldehyde derivatives of arbekacin and neomycin modified by AAC(6 ′ )-Ian in the presence of acetyl-CoA, were the same as those for AAC(6 ′ )-Iad, which was previously characterized and found to modify the 6 ′ -position of aminoglycosides. 7 These results also indicate that AAC(6 ′ )-Ian acetylates the amino group at the 6 ′ -position of aminoglycosides using an acetyl-CoA as a cofactor. AAC(6 ′ )-Ian modified arbekacin, one of the potent aminoglycosides against Gram-positive and Gram-negative bacteria ( Table 2 ). The effect of acetylation at the 6 ′ -position of arbekacin is controversial, as it was considered to result in nearly no loss of the antimicrobial effect of arbekacin in some previous reports. 8, 24 However, the production of AAC(6 ′ )-Ian increased the MIC of arbekacin from 0.25 to 8 mg/L, i.e. to the moderate resistance level in E. coli. Enzymes similar to AAC(6 ′ ) such as AAC(6 ′ )-Iad, AAC(6 ′ )-Iaj and AAC(6 ′ )-Iag that confer moderate resistance to arbekacin have been identified in Acinetobacter sp. and P. aeruginosa 7, 10, 11 and this peculiar effect against arbekacin was generally attributed to lower K m and/or higher k cat values against arbekacin. AAC(6 ′ )-Ian, in addition to AAC(6 ′ )-Iad, AAC(6 ′ )-Iaj and AAC(6 ′ )-Iag, would have high catalytic activity against arbekacin. AAC(6 ′ )-group enzymes can commonly modify the 6 ′ -position of aminoglycosides, but their substrate specificity for aminoglycosides may be highly variable considering their large diversity in amino acid constitution (Figure 1 ).
In addition, it is also possible that the expression of aac(6 ′ )-Ian may be enhanced through the original promoter regions or insertion of an upstream IS1106 element, resulting in an increase in the MIC of arbekacin. Further genetic and enzymatic characterization is necessary to explain the elevation of the MIC of arbekacin conferred by aac(6 ′ )-Ian.
Conclusions
We report here a novel plasmid-mediated amikacin acetyltransferase, AAC(6 ′ )-Ian, and ESBL, TLA-3, from a S. marcescens clinical isolate. Our results suggest that Enterobacteriaceae are still acquiring new variants of AAC(6 ′ ) group enzymes as the mechanisms for resistance to aminoglycosides including amikacin. In Enterobacteriaceae, the prevalence of amikacin resistance is still low (,1%) in Japan (http://www.nih-janis.jp/report/kensa.html), compared with the resistance rate for other classes of antibiotics such as third-generation cephalosporins and fluoroquinolones.
Thus, it appears that the potency of amikacin is still sufficient to make it effective for the treatment of infectious diseases caused by Enterobacteriaceae. However, increased use of amikacin would promote the spread of resistance determinants; thus, continuous monitoring is necessary to prevent and control the further spread of resistance determinants such as amikacin acetyltransferases including AAC(6 ′ )-Ian to allow aminoglycosides to continue to be used for treatment of bacterial infectious diseases.
